Figure 5
From: The role of membrane excitability in pancreatic β-cell glucotoxicity
Chronic pharmacologic manipulation of membrane excitability alters insulin content and secretion. (a) Insulin content in WT islets incubated for 10 days in 3 mM and 30 mM glucose, or plus the addition of the KATP channel inhibitor glibanclamide (1 µM) or the activator diazoxide (250 mM), or insulin (20 nM). Significant differences *p < 0.05 with respect to control under the same condition, non-significant are not indicated in the figure. Insulin secretion response to acute low (light grey bars) or high (dark grey bars). Glucose stimulated insulin secretion on WT islets chronically exposed to low glucose (b) or high glucose (c) plus glibenclamide or diazoxide. Significant differences *p < 0.05 with respect to chronic glucose alone under the same stimulatory condition, non-significant differences are not indicated in the figures. Inserts represent insulin secretion as a fraction of content.
